NeuScience
NeuScience identifies single-cell phenotypic biomarkers to improve prediction and discovery across solid tumor cancers. The company pairs high-throughput, patient-derived cell assays and single-cell phenotypic screening with computer vision and deep learning to detect clinically validated phenotypes linked to tumorigenesis, metastasis, toxicity, and drug resistance. Its platform provides single-cell sensitivity and uses patient tumor heterogeneity to increase translational relevance. NeuScience operates as a B2B platform serving drug developers, diagnostics teams, and research institutions. The technology targets pan-cancer biomarker discovery to accelerate therapeutic and diagnostic programs.
NeuScience
NeuScience identifies single-cell phenotypic biomarkers to improve prediction and discovery across solid tumor cancers. The company pairs high-throughput, patient-derived cell assays and single-cell phenotypic screening with computer vision and deep learning to detect clinically validated phenotypes linked to tumorigenesis, metastasis, toxicity, and drug resistance. Its platform provides single-cell sensitivity and uses patient tumor heterogeneity to increase translational relevance. NeuScience operates as a B2B platform serving drug developers, diagnostics teams, and research institutions. The technology targets pan-cancer biomarker discovery to accelerate therapeutic and diagnostic programs.